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Abstract 
Objective: We investigated the discrepancy between clinical and PCR-based diagnosis of COVID-19. We compared 
results of ten patients with mild to severe COVID-19. Respiratory samples from all cases were tested on the Roche 
SARS-CoV-2 (Cobas) assay, Filmarray RP2.1 (bioMereiux) and TaqPath™ COVID19 (Thermofisher) PCR assays.
Results: Laboratory records of ten patients with mild to severe COVID-19 were examined. Initially, respiratory 
samples from the patients were tested as negative on the SARS-CoV-2  Roche® assay. Further investigation using the 
 BIOFIRE® Filmarray RP2.1 assay identified SARS-CoV-2 as the pathogen in all ten cases. To investigate possible discrep-
ancies between PCR assays, additional testing was conducted using the TaqPath™ COVID19 PCR. Eight of ten samples 
were positive for SARS-CoV-2 on the TaqPath assay. Further, Spike gene target failures (SGTF) were identified in three 
of these eight cases. Discrepancy between the three PCR assays could be due to variation in PCR efficiencies of the 
amplification reactions or, variation at primer binding sites. Strains with SGTF indicate the presence of new SARS-
CoV-2 variant strains. Regular modification of gene targets in diagnostic assays may be necessary to maintain robust-
ness and accuracy of SARS-CoV-2 diagnostic assays to avoid reduced case detection, under-surveillance, and missed 
opportunities for control.
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Introduction
Robust diagnostic testing for SARS-CoV-2 is integral to 
disease surveillance and control of COVID-19. Reverse-
transcription polymerase chain reaction (RT-PCR) based 
assays are the most widely used assay to detect RNA 
viruses. Selection of target genes for diagnostic assays is 
critical and most diagnostic assays in use include two or 
more gene targets to maximize diagnostic accuracy (sen-
sitivity and specificity) [1].
SARS-CoV-2 was identified in December 2019 as 
a beta-coronavirus of the Sarbecovirus family, with a 
positive-sense RNA genome of 29.9 kb in size, fourteen 
open reading frames (orf) encoding accessory nonstruc-
tural viral proteins, the nucleocapsid (N), membrane 
(M), spike (S), and envelope (E) structural proteins [2]. In 
order for SARS-CoV-2 testing to be reliable, it is neces-
sary that assays that identify viral RNA should be con-
sistent and comparable. When recommendations for 
SARS-CoV-2 diagnostics were first made, the E gene 
and RdRp were amongst recommended potential target 
geness [3]. The E gene is known to have higher sensitivity 
while the inclusion of the N, S, and RNA dependent RNA 





2 Department of Pathology and Laboratory Medicine, Aga Khan 
University, Karachi, Pakistan
Full list of author information is available at the end of the article
Page 2 of 5Mushtaq et al. BMC Res Notes          (2021) 14:316 
No test is 100% accurate and false-negative results with 
commercially available diagnostic assays have been docu-
mented since the early days of the pandemic [5]. False-
negative results in the context of symptomatic COVID-19 
illness may have several determinants, such as the clini-
cal specimen type (sputum and bronchoalveolar lavage 
have higher detection rates than nasal and naso- or oro-
pharyngeal specimens) [2], temporal variation in viral 
shedding [6], as well as diagnostic primer/probe mis-
matches with infecting SARS-CoV2 virus sequence [7]. 
However, in the context of increasing reports of SARS-
CoV-2 variants seeing false negative results in diagnostic 
tests are of particular concern, as there is a wider impli-
cation on misidentification of asymptomatic cases as 
well, particularly [8, 9].
Main text
Methods
Patient specimens were collected from cases admitted 
into the COVID-19 unit at The Aga Khan University 
Hospital, Karachi, Pakistan. Inclusion criteria cases were 
those who had a high clinical suspicion for COVID-19 
but had a negative SARS-CoV-2 PCR test conducted at 
the time of their hospital admission using the SARS-
CoV-2  Cobas® 6800 assay (Roche diagnostics Rotkreuz, 
Switzerland). The following were considered as signs 
of COVID-19: classical presentation in terms of signs 
and symptoms, need for supplemental oxygen support, 
deranged inflammatory parameters and absence of alter-
native diagnosis. Exclusion criteria were cases with the 
abovementioned clinical signs who had an alternative 
cause for their respiratory illness and those who had a 
positive SARS-CoV-2 PCR results.
Patients were diagnosed with COVID-19 based on clin-
ical, laboratory and radiological parameters which were 
used to assess the severity of disease. Clinical param-
eters included physical signs like tachypnea, tachycar-
dia, hypoxia  (SpO2 < 94% at room air), while laboratory 
investigations included hypoxemia  (PaO2 < 80  mm Hg), 
hyperferritinemia, raised LDH and CRP. Radiologically, 
patients were assessed on the basis of Computerised 
tomography (CT) scan or X-ray chest.
COVID-19 severity was assessed on the basis of need 
for supplemental oxygen support, raised levels of inflam-
matory markers and more than 50% involvement of lungs 
on a CT scan or X- ray chest. Severity was ranked as per 
the WHO ordinal scale [10]. In each case, nasopharyn-
geal swab specimens were first tested for SARS-CoV-2 
RNA using the SARS-CoV-2  Cobas® (Roche diagnos-
tics Rotkreuz, Switzerland) targeting orf1-ab and E 
genes. In the case that the SARS-CoV-2 Roche RT-PCR 
was found to be negative, a second PCR was conducted 
using the  BIOFIRE® Filmarray RP2.1 test (bioMereiux, 
Marcy-l’Étoile, France) which includes four bacterial and 
18 viral pathogen targets i.e. Adenovirus, influenza A 
viruses H1, 2009H1, H3 (FluA-H1, FluA-2009H1, FluA-
H3), influenza B virus (FluB), parainfluenza virus types 
1–4 (Para 1–4), coronaviruses 229E, HKU1, OC43, and 
NL63 (CoV-HKU1, NL63, 229E, OC43), MERS-CoV 
(MERS coronavirus), human metapneumovirus (hMPV), 
Respiratory Syncytial Virus (RSV), human rhinovirus/
enterovirus (Rhino/Entero), Chlamydia pneumoniae, 
Mycoplasma pneumoniae, Bordetella pertussis, and Bor-
detella parapertussis in addition to SARS-CoV2 (S and 
M gene gene targets). All the RT-PCR assays were con-
ducted at the Aga Khan University, Karachi. SARS-CoV-2 
 Cobas® and  BIOFIRE® Filmarray RP2.1 tests were con-
ducted at the AKUH Clinical Laboratories which are 
accredited by the College of American Pathologists. For 
further investigation of discrepancies, a third PCR was 
conducted using the TaqPath™ COVID19 (Thermo, 
Applied Biosystems, USA) assay (S, N and orf1ab gene 
targets) at the AKU Research Laboratory. Assay details 
are provided in Additional file 1.
Results
We report on ten patients with COVID-19 from Karachi, 
Pakistan from 18th January to 18th February 2021, pre-
senting to acute care at a tertiary hospital. The patients 
were investigated for COVID-19 based on their clinical 
presentation. They were mostly aged 65–74 years (60%), 
followed by two cases aged > 75  years and two below 
54  years of age, Table  1. Patients had between five and 
forty days of illness with a median period of 8 days. Lab-
oratory parameters found to be raised in all cases were: 
hyperferritinemia, high biomarker levels (C-reactive pro-
tein, D-dimer), details not shown. Chest imaging showed 
ground-glass opacities or bilateral parenchymal infil-
trates, and high population prevalence in all cases. Res-
piratory samples tested by PCR for SARS-CoV-2 using 
the SARS-CoV-2 Cobas Roche assay were negative in 
all cases. Due to a high clinical suspicion for COVID-
19, samples were further set for testing on the Filmarray 
RP2.1 platform. In all ten cases, Filmarray results indi-
cated SARS-CoV-2 RNA to be present in the respiratory 
samples.
To further investigate this, the same ten respiratory 
specimens tested by Filmarray test were subsequent tested 
for the presence of SARS-CoV-2 RNA on the TaqPath™ 
COVID19 assay. Here we found, eight respiratory speci-
mens to be positive and two were negative (Table 1). All 
three gene targets in the TaqPath assay (Orf1ab, N and 
S) were detected in six samples. In one sample N and S 
were detected but Orf1ab target amplification was absent. 
S gene target failure (SGTF) was identified in three speci-
mens. The CT values of gene targets amplified in the 
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TaqPath assay were CT 31 and below indicating, high to 
medium viral loads of SARS-CoV-2 [11].
Discussion
Our data suggest show variations between diagnostic 
platforms for SARS-CoV-2. A summary of differential 
commercial RT-PCR test results and possible explana-
tions are given in Table  1. Single nucleotide mismatch 
in primer/ probe, especially in the 3′ binding region, 
may result in failure of target binding and false-negative 
results [6]. The orf1ab, N, and S regions are shown to be 
the most mutable in SARS-CoV-2, whilst E gene and M 
gene have been reported to be relatively less error prone 
[7]. Genomic sequencing would be necessary to further 
delineate the assumed polymorphisms in SARS-CoV-2 
orf1ab, N, E, and S genes that could result in the discrep-
ancies identified. However, as sequences of target regions 
in commercial assays are proprietary, a direct compari-
son between the binding regions of orf1ab in the Roche 
and TaqPath assays; and of the S region in the Filmarray 
and TaqPath assays cannot be made.
The TaqPath COVID19 assay has been used to screen 
for UK Variant of Concern (B.1.1.7) with SGTF used as 
a surrogate marker for H69-V70 variant detection [8]. 
We have limited data on genomic surveillance of SARS-
CoV-2 in Pakistan however, we have recently identified 
the introduction of B.1.1.7 lineage strains (unpublished 
data, sequence submitted). The variability observed in the 
three cases with S gene drop-out suggests the presence 
of new variants. Importantly, given the CT values of the 
gene targets detected in each case by the TaqPath assay, 
the samples had a medium to high viral load. Therefore, 
it is unlikely that discrepancy between SARS-CoV-2 diag-
nosis between assays was due to variation between assay 
sensitivity, further supporting our hypothesis.
These cases we present illustrate the importance of 
taking into account both the quality of the diagnostic 
assay and its appropriate design strategy to best capture 
SARS-CoV-2 strains moving forward. This report is a 
problem statement and has not made any comparisons 
or tested any hypotheses. We suggest that the issue of 
diagnostic test discrepancy be further studied through 
systematic research. While keeping primer and probe 
information proprietary is the norm, the medical and 
research community will benefit from requests from 
scientists to reveal further information, which is often 
not made available even upon request [12]. We pro-
pose frequent evaluation of national databases of viral 
genome sequences to inform standards on diagnostic 
assays. Such an initiative can advise on targets with 
low mutation frequency, such that > 99% of circulat-
ing variants are detectable using selected primers and 
probes. Further, in keeping with the rapidly evolving 
nature of the SARS-CoV-2 genome it is of particular 
consequence that there be a regular review of the target 
primers being used and an improvement of diagnostic 
assays to keep up the expected sensitivity and specific-
ity required of diagnostic assays for COVID-19.
Limitations
Our results are subject to inherent limitation due to 
small sample size of the study. Further, as we do not have 
genome sequences available of the SARS-CoV-2 strains 
described in the study, we cannot ascertain the polymor-
phisms present in the genomes. Further, due to the pro-
prietary nature of the commercial assays used it would 
not be possible to associate sequence variations with dif-
ferential amplification frequencies of the PCR tests.
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